Amid IPO rumors, this biotech unicorn lands ex-Bayer exec as fourth CEO in 22 months
June 10, 2019 at 17:25 PM EDT
Hans Bishop was at Chiron, Bayer and led Juno Therapeutics through its $9 billion acquisition last year by Celgene.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|